These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33388397)

  • 61. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
    Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
    JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
    Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of ischemic and bleeding risk scores in non-ST elevation acute coronary syndromes.
    Amador P; Santos JF; Gonçalves S; Seixo F; Soares L
    Acute Card Care; 2011 Jun; 13(2):68-75. PubMed ID: 21517669
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores.
    Montalto C; Crimi G; Morici N; Piatti L; Grosseto D; Sganzerla P; Tortorella G; De Rosa R; De Luca L; De Luca G; Palmerini T; Valgimigli M; Savonitto S; De Servi S
    Int J Cardiol; 2021 Apr; 328():22-28. PubMed ID: 33279593
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
    Kim C; Hong SJ; Shin DH; Kim BK; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Am Heart J; 2019 Jun; 212():45-52. PubMed ID: 30933857
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry.
    Nakamura M; Kadota K; Takahashi A; Kanda J; Anzai H; Ishii Y; Shibata Y; Yasaka Y; Takamisawa I; Yamaguchi J; Takeda Y; Harada A; Motohashi T; Iijima R; Uemura S; Murakami Y;
    J Am Heart Assoc; 2020 May; 9(10):e015439. PubMed ID: 32394794
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of RISK-PCI, GRACE, TIMI risk scores for prediction of major adverse cardiac events in patients with acute coronary syndrome.
    Jakimov T; Mrdović I; Filipović B; Zdravković M; Djoković A; Hinić S; Milić N; Filipović B
    Croat Med J; 2017 Dec; 58(6):406-415. PubMed ID: 29308832
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incidence and predictors of bleeding in ACS patients treated with PCI and prasugrel or ticagrelor: An analysis from the RENAMI registry.
    D'Ascenzo F; Grosso A; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Ali HH; Magnani G; Autelli M; Blanco PF; Garay A; Quadri G; Marra WG; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Raposeiras-Roubin S
    Int J Cardiol; 2018 Dec; 273():29-33. PubMed ID: 30228021
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
    Jiang M; You JHS
    Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y
    Flores-Blanco PJ; Cambronero-Sánchez F; Raposeiras-Roubin S; Abu-Assi E; Leithold G; Cobas-Paz R; Rodríguez Serrano AI; Calvo-Iglesias F; Valdés M; Januzzi JL; Iñiguez-Romo A; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):538-544. PubMed ID: 29146484
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of Dual versus Single Antiplatelet Therapy on Major Cardiovascular Outcomes in Patients with Acute Coronary Syndrome in the Arabian Gulf.
    Al-Zakwani I; Al-Lawati J; Alsheikh-Ali AA; Almahmeed W; Rashed W; Al-Mulla A; Zubaid M
    Med Princ Pract; 2020; 29(2):181-187. PubMed ID: 31533118
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study.
    Stepinska J; Wojtkowska I; Annemans L; Danchin N; Pocock SJ; de Werf FV; Medina J; Bueno H
    Curr Vasc Pharmacol; 2020; 18(1):92-99. PubMed ID: 30588886
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry.
    Rasia M; Solinas E; Marino M; Guastaroba P; Menozzi A; Cattabiani MA; Tadonio I; De Palma R; Vignali L
    J Thromb Thrombolysis; 2017 Nov; 44(4):466-474. PubMed ID: 28994036
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes.
    Schoos M; Power D; Baber U; Sartori S; Claessen B; Camaj A; Steg P; Ariti C; Weisz G; Witzenbichler B; Henry T; Cohen D; Antoniucci D; Krucoff M; Hermiller J; Gibson C; Chieffo A; Moliterno D; Colombo A; Pocock S; Dangas G; Mehran R
    Am J Cardiol; 2019 Mar; 123(5):709-716. PubMed ID: 30612724
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characteristics, management and outcomes of patients with acute coronary syndrome and prior coronary artery bypass surgery: findings from the second Gulf Registry of Acute Coronary Events.
    Al-Aqeedi R; Sulaiman K; Al Suwaidi J; Alhabib K; El-Menyar A; Panduranga P; Alshiekh-Ali A; Al Saif S
    Interact Cardiovasc Thorac Surg; 2011 Dec; 13(6):611-8. PubMed ID: 21920933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.